Early prediction of the bactericidal and bacteriostatic effect of imipenem and doxycycline using tabletop scanning electron microscopy.
bacterial morphology
bactericidal effect
bacteriostatic effect
rapid methods in microbiology
scanning electron microscopy
tabletop SEM
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2024
2024
Historique:
received:
11
05
2024
accepted:
02
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
Our work aims at establishing a proof-of-concept for a method that allows the early prediction of the bactericidal and bacteriostatic effects of antibiotics on bacteria using scanning electron microscopy (SEM) as compared to traditional culture-based methods. We tested these effects using Imipenem (bactericidal) and Doxycycline (bacteriostatic) with several strains of sensitive and resistant Our method revealed total agreement with the CFU method and classic definition by visualizing the effect of the antibiotic at 60 minutes and 120 minutes using SEM. This early prediction allows a rapid and early identification of the bactericidal and bacteriostatic effects as compared to culture that would take a minimum of 18 hours. This has several future applications in the development of SEM-automated assays coupled to machine learning models that identify the antibiotic effect and facilitate determination of bacterial susceptibility.
Identifiants
pubmed: 39268484
doi: 10.3389/fcimb.2024.1431141
pmc: PMC11390654
doi:
Substances chimiques
Anti-Bacterial Agents
0
Imipenem
71OTZ9ZE0A
Doxycycline
N12000U13O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1431141Informations de copyright
Copyright © 2024 Zmerli, Hodzic, Bellali, Azar and Bou Khalil.
Déclaration de conflit d'intérêts
The authors declare that this study received funding from Hitachi High-Tech Corporation. Personal fees of AH, SB, and JB are paid through a collaborative contract from the company Hitachi High-Tech Corporation. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Microbiol Rev. 1992 Oct;5(4):420-32
pubmed: 1423219
Antibiotics (Basel). 2023 Aug 19;12(8):
pubmed: 37627760
Cell Metab. 2019 Aug 6;30(2):251-259
pubmed: 31279676
Microorganisms. 2021 May 28;9(6):
pubmed: 34071713
Sci Rep. 2023 Jul 12;13(1):11258
pubmed: 37438469
Comput Struct Biotechnol J. 2023 Jul 11;21:3627-3638
pubmed: 37501704
Clin Chem. 2021 Dec 30;68(1):91-98
pubmed: 34969098
J Antimicrob Chemother. 2015 Feb;70(2):382-95
pubmed: 25266070
Clin Infect Dis. 2004 Mar 15;38(6):864-70
pubmed: 14999632
Clin Infect Dis. 2009 Dec 1;49(11):1749-55
pubmed: 19857164
Clin Infect Dis. 2009 Aug 15;49(4):543-51
pubmed: 19583519
Analyst. 2024 Feb 26;149(5):1597-1608
pubmed: 38291984
Nature. 2016 Jan 21;529(7586):336-43
pubmed: 26791724
Front Cell Infect Microbiol. 2020 Oct 19;10:540898
pubmed: 33194788